- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ranbaxy chief steps down
1 June 2009
Chairman and chief executive of Ranbaxy Laboratories, Malvinder Singh, has stepped down, handing more control over the generic drug maker to its Japanese owner Daiichi Sankyo.
Mr Singh's family founded the company and it has since become one of India's best-known multinational companies. He will be replaced as chief executive by Atul Sobti, currently the company's chief operating officer and Tsutomo Une, Daiichi's senior executive officer, will take over his responsibilities as chairman.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
